A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder

To be part of this study, you would need to have a specific type of bladder cancer that has spread into the muscle, but not yet to distant parts of your body. Your diagnosis must have been quite recent, within about four months before starting the study. It's important that any tumours inside your bladder either aren't there anymore, or are quite small (3cm or less) after a procedure to remove them. You also need to be well enough to undergo major surgery like bladder removal, should that be needed later.

There are also some things that would mean you couldn't join. For example, if you've already had certain cancer treatments like chemotherapy or radiation very recently. We also couldn't include you if your cancer has already spread to lymph nodes or other parts of your body, or if you have specific types of bladder cancer cells that are not being studied here. The doctors will check your general health, like how well your thyroid is working and if you have any ongoing issues from previous surgeries.

If you decide to take part in this study, you'll go through several stages. First, there's a 'screening' phase where various tests will be done to make sure the study is right for you. If you qualify, you'll then enter the 'treatment' phase, where you'll receive either TAR-200 combined with cetrelimab, or cetrelimab on its own. The specific schedule for these treatments will be explained to you in detail.

Throughout the treatment phase, you'll have regular visits to the clinic for check-ups, blood tests, and scans. These are to see how you're responding to the treatment, monitor any side effects, and check drug levels in your body. After the treatment period, there will be a 'follow-up' phase where doctors continue to monitor your health. The total time you'd be involved in the study, from beginning to end, could be up to two and a half years.